28.8 C
New York
Wednesday, June 3, 2026

Tag: license application

newssourceFORcompanyinformationcontent1marketreleases

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026...

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -

Duke Energy seeks to extend operations for another 50 years at Bad Creek, supporting unprecedented growth in the Carolinas

For more than three decades, the pumped storage hydro station in South Carolina has performed a vital role as the largest "battery" on the...

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

TransferMate submits application for Bahrain license, as it expands its footprint in the Middle East

DUBLIN, Aug. 13, 2025 /PRNewswire/ -- TransferMate, the world's leading provider of embedded B2B payments infrastructure as a service (IaaS), has today announced it...

Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – 
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

Immix Biopharma Announces Other Serious Diseases Strategy

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –

ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

Bragar Eagel & Squire, P.C. Is Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm

NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits

If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLicense application

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers